• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Anteris Technologies Global Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    12/4/25 6:02:53 AM ET
    $AVR
    Industrial Specialties
    Health Care
    Get the next $AVR alert in real time by email
    false000201151400020115142025-12-032025-12-03

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     


    FORM 8-K
     


    CURRENT REPORT
    Pursuant to Section 13 OR 15(d)
    of The Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): December 3, 2025
     


    Anteris Technologies Global Corp.
    (Exact name of registrant as specified in its charter)
     


    Delaware
    001-42437
    99-1407174
    (State or Other Jurisdiction of Incorporation)
    (Commission File Number)
    (I.R.S. Employer Identification No.)

    Toowong Tower, Level 3, Suite 302
       
    9 Sherwood Road
       
    Toowong, QLD
       
    Australia
     
    4066
    (Address of Principal Executive Offices)
     
    (Zip Code)

    Registrant’s telephone number, including area code: +61 7 3152 3200

    Not Applicable
    (Former name or former address, if changed since last report)
     


    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
     
    Trading
    Symbol(s)
     
    Name of each exchange
    on which registered
    Common Stock, par value $0.0001 per share
     
    AVR
     
    The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 5.07
    Submission of Matters to a Vote of Security Holders
     
    On December 3, 2025, Anteris Technologies Global Corp. (the “Company”) held its Annual Meeting of its stockholders (the “Annual Meeting”) at which a quorum was present. The matters listed below were submitted to a vote of the Company’s stockholders at the Annual Meeting through the solicitation of proxies. Detailed descriptions of the proposals are included in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on November 10, 2025 (the “Proxy Statement”).
     
    A total of 20,980,141 shares of the Company’s common stock were present at the Annual Meeting in person, by virtual attendance, or by proxy, which represents approximately 54.6% of the shares of common stock outstanding as of October 30, 2025, which was the record date for the Annual Meeting.
     
    Proposal 1A: Election of John Seaberg as Director

    The Company’s stockholders approved the election of John Seaberg as a Class I director to serve until the 2028 annual meeting of stockholders and until his successor is duly elected and qualified or until the earlier of his death, resignation, disqualification or removal. The final voting results are as follows:
     
    Votes For
    Votes Against
    Abstentions
    14,305,918
    2,366,543
    580,841

    Proposal 1B: Election of Gregory Moss as Director

    The Company’s stockholders approved the election of Gregory Moss as a Class I director to serve until the 2028 annual meeting of stockholders and until his successor is duly elected and qualified or until the earlier of his death, resignation, disqualification or removal. The final voting results are as follows:

    Votes For
    Votes Against
    Abstentions
    15,653,027
    1,004,903
    595,372
                     
    Proposal 2: Appointment of KPMG
     
    The Company’s stockholders approved the ratification of the appointment of KPMG as the Company’s independent registered public accounting firm for the 2025 fiscal year. The final voting results are as follows:
     
    Votes For
    Votes Against
    Abstentions
    20,620,868
    146,666
    212,607

    Proposal 3: Grant of RSUs to Wayne Paterson (IPO)
     
    The Company’s stockholders approved, for the purposes of ASX Listing Rule 10.14 and for all other purposes, the grant of 1,000,000 restricted stock units (“RSUs”) to Wayne Paterson in connection with the Company's U.S. initial public offering (the “IPO”), on the terms and conditions set out in the Proxy Statement. The final voting results are as follows:
     
    Votes For
    Votes Against
    Abstentions
    13,208,624
    1,658,798
    2,385,880
     
    Proposal 4: Grant of RSUs to John Seaberg (IPO)
     
    The Company’s stockholders approved, for the purposes of ASX Listing Rule 10.14 and for all other purposes, the grant of 83,333 RSUs to John Seaberg in connection with the IPO, on the terms and conditions set out in the Proxy Statement. The final voting results are as follows:
     
    Votes For
    Votes Against
    Abstentions
    13,232,053
    2,002,822
    2,018,427

    Proposal 5: Grant of RSUs to Stephen Denaro (IPO)
     
    The Company’s stockholders approved, for the purposes of ASX Listing Rule 10.14 and for all other purposes, the grant of 41,666 RSUs to Stephen Denaro in connection with the IPO, on the terms and conditions set out in the Proxy Statement. The final voting results are as follows:
     
    Votes For
    Votes Against
    Abstentions
    13,235,783
    1,999,302
    2,018,217

    Proposal 6: Election of Gregory Moss as Director
     
    The Company’s stockholders approved, for the purposes of ASX Listing Rule 10.14 and for all other purposes, the grant of 52,742 RSUs to Gregory Moss in connection with appointment to the Board, on the terms and conditions set out in the Proxy Statement. The final voting results are as follows:
     
    Votes For
    Votes Against
    Abstentions
    13,526,644
    1,707,591
    2,019,067

    Proposal 7: Grant of RSUs to David Roberts

    The Company’s stockholders approved, for the purposes of ASX Listing Rule 10.14 and for all other purposes, the grant of 52,742 RSUs to David Roberts in connection with i.e. "David Roberts in connection with his appointment" appointment to the Board, on the terms and conditions set out in the Proxy Statement. The final voting results are as follows:
     
    Votes For
    Votes Against
    Abstentions
    13,531,294
    1,702,941
    2,019,067
     

    Proposal 8: Grant of RSUs to John Seaberg

    The Company’s stockholders approved, for the purposes of ASX Listing Rule 10.14 and for all other purposes, the grant of $250,000 (in grant date value) of RSUs to John Seaberg in connection with the annual meeting for the 2025 fiscal year, on the terms and conditions set out in the Proxy Statement. The final voting results are as follows:
     
    Votes For
    Votes Against
    Abstentions
    13,102,222
    2,166,611
    1,984,469

    Proposal 9: Grant of RSUs to Stephen Denaro
     
    The Company’s stockholders approved, for the purposes of ASX Listing Rule 10.14 and for all other purposes, the grant of $125,000 (in grant date value) of RSUs to Stephen Denaro in connection with the annual meeting for the 2025 fiscal year, on the terms and conditions set out in the Proxy Statement. The final voting results are as follows:
     
    Votes For
    Votes Against
    Abstentions
    13,090,812
    2,173,577
    1,988,913

    Proposal 10: Grant of RSUs to Gregory Moss
     
    The Company’s stockholders approved, for the purposes of ASX Listing Rule 10.14 and for all other purposes, the grant of $61,644 (in grant date value) of RSUs to Gregory Moss in connection with the annual meeting for the 2025 fiscal year, on the terms and conditions set out in the Proxy Statement. The final voting results are as follows:
     
    Votes For
    Votes Against
    Abstentions
    13,150,782
    2,112,607
    1,989,913

    Proposal 11: Grant of RSUs to David Roberts
     
    The Company’s stockholders approved, for the purposes of ASX Listing Rule 10.14 and for all other purposes, the grant of $61,644 (in grant date value) of RSUs to David Roberts in connection with the annual meeting for the 2025 fiscal year, on the terms and conditions set out in the Proxy Statement. The final voting results are as follows:
     
    Votes For
    Votes Against
    Abstentions
    13,143,511
    2,119,468
    1,990,323

    Proposal 12: Adjustments for Employee Incentive Plan Exercise Price
     
    The Company’s stockholders approved, for the purposes of ASX Listing Rule 6.23.4 and for all other purposes, adjustments to the exercise price of certain stock options previously granted under the Company’s Employee Incentive Plan, on the terms and conditions set out in the Proxy Statement. The final voting results are as follows:
     
    Votes For
    Votes Against
    Abstentions
    13,230,229
    2,029,493
    1,993,580

    Proposal 13: Amendments to 2017 and 2020 Incentive Plans
     
    The Company’s stockholders approved, for the purposes of ASX Listing Rule 6.23.4 and for all other purposes, amendments to the terms of stock options previously granted under the Company’s 2017 Incentive Plan and 2020 Incentive Plan, as set out in the Proxy Statement. The final voting results are as follows:
     
    Votes For
    Votes Against
    Abstentions
    13,177,832
    2,076,481
    1,998,989


    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    Anteris Technologies Global Corp.
     

    Date: December 3, 2025
     
     
     
    By:
    /s/ Wayne Paterson
     
    Name:
    Wayne Paterson
     
    Title: Vice Chairman and Chief Executive Officer



    Get the next $AVR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVR

    DatePrice TargetRatingAnalyst
    1/8/2025$20.00Buy
    Lake Street
    1/7/2025$15.00Buy
    TD Cowen
    1/7/2025$9.00Overweight
    Cantor Fitzgerald
    1/7/2025$22.00Overweight
    Barclays
    More analyst ratings

    $AVR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Anteris Technologies Global Corp. with a new price target

    Lake Street initiated coverage of Anteris Technologies Global Corp. with a rating of Buy and set a new price target of $20.00

    1/8/25 8:52:46 AM ET
    $AVR
    Industrial Specialties
    Health Care

    TD Cowen initiated coverage on Anteris Technologies Global Corp. with a new price target

    TD Cowen initiated coverage of Anteris Technologies Global Corp. with a rating of Buy and set a new price target of $15.00

    1/7/25 9:02:46 AM ET
    $AVR
    Industrial Specialties
    Health Care

    Cantor Fitzgerald initiated coverage on Anteris Technologies Global Corp. with a new price target

    Cantor Fitzgerald initiated coverage of Anteris Technologies Global Corp. with a rating of Overweight and set a new price target of $9.00

    1/7/25 9:00:55 AM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves

    MINNEAPOLIS and BRISBANE, Australia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) today released 30-day clinical outcomes for the DurAVR® THV in one hundred severe aortic stenosis patients with small aortic annuli (aortic annulus area 404 ± 37mm2). The DurAVR® THV demonstrated single digit mean gradients, large effective orifice areas (EOAs), no moderate or severe paravalvular leaks and no valve related mortality, with 97% freedom from moderate or severe prosthesis-patient mismatch* (PPM) in a cohort of small annuli patients similar to the one reported in the SMART Trial1. The late-breaking science was presented b

    11/17/25 6:00:00 AM ET
    $AVR
    Industrial Specialties
    Health Care

    Anteris Announces Results for the Third Quarter of 2025

    MINNEAPOLIS, Minn. and BRISBANE, Australia , Nov. 12, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended September 30, 2025, and provided a corporate update. Third Quarter 2025 Highlights Continued FDA engagement during the Quarter to advance the IDE for the PARADIGM Trial, with FDA approval to commence U.S. recruitment* announced in November 2025Advanced European regulatory activities to initiate the PARADIGM Trial across

    11/12/25 5:52:49 PM ET
    $AVR
    Industrial Specialties
    Health Care

    FDA Approves Anteris's DurAVR® THV Global Pivotal Trial (the "PARADIGM Trial")

    PARADIGM: A Prospective rAndomized tRial Assessing the safety and effectiveness of the DurAVR® bIomimetic valve designed for physioloGic flow compared to CoMmercial TAVR devices MINNEAPOLIS and BRISBANE, Australia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Anteris announced today it has received U.S. Food and Drug Administration (FDA) approval to initiate PARADIGM, its global Investigational Device Exemption (IDE) clinical trial which is designed to evaluate the DurAVR® Transcatheter Heart Valve (THV) in patients with severe calcific aortic stenosis and to support a future PMA* submission. "We are extremely pleased to receive FDA approval for the PARADIGM Trial, which allows us to commence pati

    11/3/25 7:00:00 AM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Paterson Wayne

    4 - Anteris Technologies Global Corp. (0002011514) (Issuer)

    12/8/25 6:01:40 AM ET
    $AVR
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Director Denaro Stephen

    4 - Anteris Technologies Global Corp. (0002011514) (Issuer)

    12/5/25 6:30:28 PM ET
    $AVR
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Director Moss Gregory S.

    4 - Anteris Technologies Global Corp. (0002011514) (Issuer)

    12/5/25 6:30:30 PM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    SEC Filings

    View All

    SEC Form EFFECT filed by Anteris Technologies Global Corp.

    EFFECT - Anteris Technologies Global Corp. (0002011514) (Filer)

    12/12/25 12:15:04 AM ET
    $AVR
    Industrial Specialties
    Health Care

    SEC Form 424B3 filed by Anteris Technologies Global Corp.

    424B3 - Anteris Technologies Global Corp. (0002011514) (Filer)

    12/11/25 4:17:55 PM ET
    $AVR
    Industrial Specialties
    Health Care

    Anteris Technologies Global Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Anteris Technologies Global Corp. (0002011514) (Filer)

    12/4/25 6:02:53 AM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    Leadership Updates

    Live Leadership Updates

    View All

    Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

    MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. "On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company" commented John Seaberg, Chairman o

    6/9/25 10:52:06 PM ET
    $AVR
    $LMAT
    Industrial Specialties
    Health Care
    Medical/Dental Instruments